← Human Trials & Peer-Reviewed Studies
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18
Plain-language guide to PMID 12706919 (2003): randomized controlled trial of BNP (Nesiritide) in 1,676 patients.
Key Facts
- PMID
- 12706919
- Journal
- Journal of the American College of Cardiology
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- Morrow DA et al. (10 authors)
- DOI
- 10.1016/s0735-1097(03)00168-2
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.
This study was designed to evaluate B-type natriuretic peptide (BNP) for risk assessment and clinical decision making over a range of cut points, alone and with cardiac troponin I (cTnI), in patients with non-ST-elevation acute coronary syndromes (ACS).
Why It Was Studied
B-type natriuretic peptide holds promise for risk stratification.
Additional evidence regarding optimal decision limits, use in combination with troponin, and use in targeting therapy is needed before acceptance into clinical use for ACS.
Who Took Part
According to the abstract, 1,676 patients were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
The researchers evaluated BNP at baseline in 1,676 patients with non-ST-elevation ACS randomized to early invasive versus conservative management.
How the Study Was Run
In design terms this was a randomized study.
The patients were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.
What Was Measured
PubMed files the paper under topics including Angina, Unstable, Atrial Natriuretic Factor, Biomarkers, Cardiotonic Agents, Heart Conduction System, Myocardial Infarction and Natriuretic Peptide, Brain.
What This Means in Plain Language
The paper is a randomized study of BNP (Nesiritide) in 1,676 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2003 (Journal of the American College of Cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.